Insider Transactions in Q4 2020 at Royalty Pharma PLC (RPRX)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2020
|
George W. Lloyd EVP, Investments & CLO |
BUY
Conversion of derivative security
|
Indirect |
500,000
+50.0%
|
-
|
|
Dec 31
2020
|
James F. Reddoch EVP & Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
400,000
+37.26%
|
-
|
|
Dec 31
2020
|
Terrance P. Coyne EVP & CFO |
BUY
Conversion of derivative security
|
Indirect |
400,000
+46.44%
|
-
|
|
Dec 31
2020
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+5.4%
|
$36,900
$45.69 P/Share
|
|
Dec 31
2020
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+8.6%
|
$36,900
$45.69 P/Share
|
|
Dec 18
2020
|
Adage Capital Partners Gp, L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
101,050
-0.26%
|
$4,446,200
$44.02 P/Share
|
|
Dec 17
2020
|
Adage Capital Partners Gp, L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,200,000
-15.65%
|
$309,600,000
$43.92 P/Share
|
|
Dec 16
2020
|
William E Ford Director |
SELL
Other acquisition or disposition
|
Indirect |
42,101
-7.24%
|
-
|
|
Oct 20
2020
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
428,420
+31.72%
|
-
|
|
Oct 20
2020
|
William E Ford Director |
BUY
Conversion of derivative security
|
Indirect |
581,870
+50.0%
|
-
|
|
Oct 20
2020
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
463,200
-100.0%
|
$19,454,400
$42.0 P/Share
|
|
Oct 20
2020
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
463,200
+50.0%
|
-
|